Entity

Immunotherapy

Cancer treatment that trains the patient's own immune system to attack tumors.

As of 2 Nov 2026Last evidence 1 Nov 2026

What is happening now

  • FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis

    Reported claim · first reported 30 Oct 2026 · 1 claim · best-carried claim: 4 separate publishers

  • Dense Longitudinal Multi Omics Reveals Microbial Metabolic Immune Succession During Immune Checkpoint Therapy

    Reported claim · first reported 28 Oct 2026 · 1 claim · best-carried claim: 2 separate publishers

  • Samsung Bioepis Keytruda Biosimilar Matches Original in Phase 1 Trial

    Reported claim · first reported 27 Oct 2026 · 1 claim · best-carried claim: 1 separate publisher

All 3 events and claims involving Immunotherapy

What changed

  • Attention Rising: 41 mentions on 2 Nov 2026, against 17 on 12 Oct 2026 (+141%).
  • State Last recorded change: wire tier went from flagged to watch on 1 Nov 2026 (8 changes recorded since 21 Oct 2026).
  • Claims No claim first reported since 1 Nov 2026.

How well we know this

808 documents · 172 publishers · 5% contain a typed assertion · last evidence 1 Nov 2026

  • Gap: assertion coverage 0.053: about 95% of mentions carry no typed assertion
  • Gap: 2 receipts withheld: no source link (the same rule the topic record applies)

In this snapshot’s daily coverage:

Reported alongside Immunotherapy

Names most often reported alongside it; bigger circles and heavier lines mean more shared documents. A dashed circle has no page of its own yet.

ChinaAI
  • Colorectal Cancer · 355 shared documents · no page of its own yet
  • Overall Survival · 187 shared documents · no page of its own yet
  • FDA · 176 shared documents · no page of its own yet
  • Lung Cancer · 166 shared documents · no page of its own yet
  • China · 122 shared documents
  • Clinical Trial · 122 shared documents · no page of its own yet
  • T-Cell · 108 shared documents · no page of its own yet
  • Clinical Trials · 108 shared documents · no page of its own yet
  • AI · 107 shared documents
  • Solid Tumors · 86 shared documents · no page of its own yet

Story momentum

Rising

The word compares 41 mentions on 2 Nov 2026 with 17 on 12 Oct 2026 (+141%); a change of less than 8% either way reads Steady.

Daily mentions +5% from 18 Sept 2026 to 2 Nov 2026, between 11 and 53 a day

How often tracked coverage mentions Immunotherapy, day by day.

Market price, cited

Not priced yet

No open prediction market prices a question materially about Immunotherapy yet. Ask about Immunotherapy

No market price on file: no prediction market prices a question about this name yet

Coverage volume and market price are separate measures.

For developers

This page is also an object: GET https://sigb.ai/api/v1/node/e/e20001c47e40d4b109d5f837 returns the same record as sb.node.v1. Or call the get_entity MCP tool at https://sigb.ai/api/mcp with name immunotherapy.

{
  "name": "immunotherapy",
  "label": "Immunotherapy",
  "asOf": "2026-11-02",
  "mentions": 75,
  "outlets": 57,
  "domains": 12,
  "node": {
    "id": "sb:e/e20001c47e40d4b109d5f837",
    "schema": "sb.node.v1",
    "rest": "https://sigb.ai/api/v1/node/e/e20001c47e40d4b109d5f837",
    "knowledgeCutoff": "2026-11-02T23:20:37.552024+00:00",
    "snapshot": "this deploy's committed data files (commit not exposed in this runtime)"
  },
  "coverageTrend": "rising",
  "history": {
    "since": "2026-10-21T13:12:56.354446+00:00",
    "changes": 8
  },
  "whereFrom": {
    "level": "counts",
    "label": "75 mentions across 12 domains",
    "children": [
      {
        "level": "reports",
        "label": "6 reports drawn on this page, each with its link",
        "children": {
          "count": 6,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "domains",
        "label": "12 coverage domains",
        "children": {
          "count": 12,
          "unfold": "expand=+1"
        }
      },
      {
        "level": "not shown",
        "label": "The other 69 mentions",
        "edge": "counted daily from tracked coverage; single mentions are not listed one by one"
      }
    ]
  }
}

The figures on this page, as data. The tool returns the full entity record.

Events involving Immunotherapy

Most-reported first, then newest. Registered events come from the event record; reported events are groups of claims about one occurrence. Claims are grouped when they were first reported within 2 days of each other and either name at least 2 of the same people, places or things besides this one, or share at least 25% of their wording. Each claim keeps its own record.

  • FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis

    Reported claim · first reported 30 Oct 2026 · 1 claim · best-carried claim: 4 separate publishers

    reported by two

  • Dense Longitudinal Multi Omics Reveals Microbial Metabolic Immune Succession During Immune Checkpoint Therapy

    Reported claim · first reported 28 Oct 2026 · 1 claim · best-carried claim: 2 separate publishers

    could not check

  • Samsung Bioepis Keytruda Biosimilar Matches Original in Phase 1 Trial

    Reported claim · first reported 27 Oct 2026 · 1 claim · best-carried claim: 1 separate publisher

    single source

Walk the record from Immunotherapy

Open where it comes from, follow a claim or a related name, and use the trail to come back. Every step says what it is, how it stands and when. Machines read the same record.

Immunotherapy

Entity.

Evidence
808 documents · 172 separate publishers · a mention shows the name is in use, not that any claim about it is true
Standing
A name from our starting list; its record is kept up to date automatically from coverage
Time
first seen 11 Mar 2026, last seen 1 Nov 2026
Measured
5% of mentions say something specific about it; the rest only name it
As of
2 Nov 2026
14 links from here

Who it moves with: the 10 names are in the map above.

What is claimed about it (3)

  • Reported by two: Reported by two sources that did not copy each other.
  • Single source: Reported by one source so far.
  • Could not check: We could not count this claim's sources, so we do not say how well it is supported.

Situations it is named in (1)

For machines: this record as JSON

Watch this

What the coverage says

Recent reporting that names Immunotherapy, newest first. Open any row to follow it to the original article.

Evidence tiers: primary source = an official public record · attributed = a named outlet, receipt linked · lead = observed, not yet receipted.

What it connects to

Related records.

Recorded history

  • 1 Nov 2026

    wire tier changed: flagged to watch

    Previous state held since 31 Oct 2026

  • 1 Nov 2026

    coverage state changed: rising to insufficient_history

    Previous state held since 31 Oct 2026

  • 31 Oct 2026

    wire tier changed: watch to flagged

    Previous state held since 22 Oct 2026

  • 31 Oct 2026

    coverage state changed: insufficient_history to rising

    Previous state held since 22 Oct 2026

  • 22 Oct 2026

    wire tier changed: flagged to watch

    Previous state held since 21 Oct 2026

  • 22 Oct 2026

    coverage state changed: rising to insufficient_history

    Previous state held since 21 Oct 2026

  • 21 Oct 2026

    wire tier changed: watch to flagged

    Previous state held since 6 Oct 2026

  • 21 Oct 2026

    coverage state changed: insufficient_history to rising

    Previous state held since 6 Oct 2026

8 changes recorded since 21 Oct 2026, newest first.

Ask about ImmunotherapyWatch Immunotherapy

Story momentum counts mentions in tracked coverage. Prices are the market’s own, cited with the venue. Informational only, not advice. As of 2 Nov 2026.